North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market, By Product Type (Robotic Systems, Instruments, Accessories), End-User (Hospitals, Path Labs, Others) – Industry Trends and Forecast to 2030.
North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Analysis and Size
According to data from the American College of Cardiology (ACC) and the American Heart Association (AHA), the incidence of Percutaneous Coronary Intervention (PCI) has been steadily increasing over the years. For instance, in the U.S., there were approximately 1.2 million PCI procedures performed almost every year.
Data Bridge Market Research analyzes that the North America robot assisted Percutaneous Coronary Intervention (PCI) market, which was USD 836.91 million in 2022, would rocket up to USD 1344.01 million by 2030, and is expected to undergo a CAGR of 6.1% during the forecast period. “Robotic Systems” is expected to dominate the product type segment of the market owing to the growing demand for better surgical methods for treatment.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Product Type (Robotic Systems, Instruments, Accessories), End-User (Hospitals, Path Labs, Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
Corindus, Inc. (U.S.), Robocath, Inc. (France), Smith+Nephew (U.K.), Medtronic (Ireland), CMR Surgical Ltd. (U.K.), Renishaw plc. (U.K.), KUKA AG (Germany), Auris Health, Inc. (U.S.), Intuitive Surgical, Inc (U.S.), Medrobotics Corporation (U.S.), CorPath Robotics (A Subsidiary of Siemens Healthineer) (U.S.), and ROBODOC (Curexo Technology Corporation) (U.S.) among others
|
|
Market Opportunities
|
|
Market Definition
Percutaneous Coronary Intervention (PCI) with robot assistance is a non-surgical approach for implanting a stent that reduces the risk of orthopedic injury and operator fatigue. PCI with robot assistance is a medical treatment for treating obstructive coronary artery disease and opening up blocked or restricted blood arteries. In comparison to traditional PCI, robot-assisted PCI has a higher rate of success and accuracy.
North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Dynamics
Drivers
- Rising Prevalence of Cardiovascular Diseases
North America has a high burden of cardiovascular diseases, including coronary artery disease. The increasing prevalence of these conditions drives the demand for advanced treatment options such as robot-assisted PCI.
- Increasing Demand for Minimally Invasive Procedures
Patients and healthcare providers are increasingly opting for minimally invasive procedures that offer shorter hospital stays, faster recovery, and reduced complications. Robot-assisted PCI provides a less invasive alternative to traditional open-heart surgery, leading to its growing demand in North America.
Opportunities
- Patient Demand for Advanced Treatment Options
Patients are increasingly seeking advanced treatment options that offer improved outcomes and faster recovery. The growing patient demand for minimally invasive procedures and the potential benefits of robot-assisted PCI present opportunities for healthcare providers to meet these demands and provide high-quality care.
- Increasing Healthcare Infrastructure and Investment
The robust healthcare infrastructure and investment in North America provide a supportive environment for the growth of robot-assisted PCI. Continued investment in healthcare facilities and access to advanced technologies can create opportunities for the adoption of robotic systems in PCI procedures.
Restraints/Challenges
- High Cost of Robot-Assisted Percutaneous Coronary Intervention (PCI) Instruments
The initial cost of acquiring robotic systems and the ongoing maintenance expenses can be significant. The high costs associated with robot-assisted PCI can limit its adoption, particularly in healthcare settings with budget constraints or reimbursement limitations.
- Limited Clinical Evidence
While robot-assisted PCI has shown promising results, there may be a need for more robust clinical evidence to support its widespread adoption. Long-term data on patient outcomes, cost-effectiveness, and comparative studies with traditional PCI procedures can help address any skepticism and encourage greater acceptance of robot-assisted intervention (PCI).
The North America robot assisted Percutaneous Coronary Intervention (PCI) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an analyst brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In January 2021, MicroPort announced the successful completion of the 10,000th implantation of its Firehawk Rapamycin Target Eluting Coronary Stent System. The achievement highlighted the continued adoption and clinical use of the company's stent system in robotic-assisted PCI procedures
- In June 2020, Auris Health announced the FDA clearance of its Monarch Platform for robotic-assisted bronchoscopic procedures. While not specifically focused on PCI, this development showcased the potential of Auris Health's robotic-assisted technology in minimally invasive interventions.
North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Scope
The North America robot assisted Percutaneous Coronary Intervention (PCI) market is segmented into two notable segments based on product type and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Robotic Systems
- Instruments
- Accessories
End-User
- Hospitals
- Path Labs
- Others
North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Regional Analysis/Insights
The North America robot assisted Percutaneous Coronary Intervention (PCI) market is analyzed and market size insights and trends are provided by product type and end-users as referenced above.
The countries covered in this market report are U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America robot assisted Percutaneous Coronary Intervention (PCI) market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having cardiac disorders.
The U.S. is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for coronary diseases, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The North America robot assisted Percutaneous Coronary Intervention (PCI) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the North America robot assisted Percutaneous Coronary Intervention (PCI) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market.
Competitive Landscape and North America Robot Assisted Percutaneous Coronary Intervention (PCI) Market Share Analysis
The North America robot assisted Percutaneous Coronary Intervention (PCI) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the North America robot assisted Percutaneous Coronary Intervention (PCI) market are:
- Corindus, Inc. (U.S.)
- Robocath, Inc. (France)
- Smith+Nephew (U.K.)
- Medtronic (Ireland)
- CMR Surgical Ltd. (U.K.)
- Renishaw plc. (U.K.)
- KUKA AG (Germany)
- Auris Health, Inc. (U.S.)
- Intuitive Surgical, Inc (U.S.)
- Medrobotics Corporation (U.S.)
- CorPath Robotics (A Subsidiary of Siemens Healthineer) (U.S.)
- ROBODOC (Curexo Technology Corporation) (U.S.)
SKU-